位置:成果数据库 > 期刊 > 期刊详情页
AS—CLB1增强泰素帝抗Lewis肺癌细胞体内外增殖作用的研究
  • ISSN号:1000-8179
  • 期刊名称:《中国肿瘤临床》
  • 时间:0
  • 分类:R734.205[医药卫生—肿瘤;医药卫生—临床医学] R392.12[医药卫生—免疫学;医药卫生—基础医学]
  • 作者机构:[1]中国人民解放军成都军区总医院肿瘤科,成都市610083, [2]浙江大学细胞生物学研究所, [3]四川师范大学生命科学学院
  • 相关基金:本文课题受国家自然科学基金资助(编号:30472064)
中文摘要:

目的:研究细胞周期蛋白B1反义全长cDNA(AS—CLB1)时抗Lewis肺癌细胞(LL/2)体内外增殖作用的影响,为将AS—CLB1联合用于人肺癌等恶性肿瘤的治疗提供实验依据。方法:(0.01nmol/L-0.1μmol/L)处理LL/2亲本(LP),LL/2空载体(LV)及LL/2/AS—CLB1(LA)三种细胞,分别于1h及24h后用MTT比色法评估对各组细胞的杀伤作用。将上述三种细胞分别接种C57BL/6小鼠,成瘤后用(15mg/kg·d)处理各组动物,3d 1次,一共4次,进行成瘤性及动物生存时间观察;流式细胞仪检测各组动物肿瘤组织细胞周期厦凋亡。结果:无论是泰素帝处理1h还是24h,LA细胞存活率较LP、LV两对照均明显降低(P〈0.05);其中处理1h后,泰素帝80nmol/L组LA细胞存活率低于对照9倍以上,处理24h后,20nmol/L组LA细胞存活率低于对照7倍左右 。LA组小鼠肿瘤体积明显小于对照(P〈0.05),接种后30天,LP组肿瘤体积大小为1981.29±318.56mm^3,LV组为1673.36±297.96mm^3,LA组仅为421.68±30.16mm^3。LA组肿瘤组织中细胞在G1期所占比例为(89.7±0.5)%,凋亡率为(79.5±1.2)%,均较对照明显增加(P〈0.05)。接种后60天,LA组尚有70%的小鼠存活,LP组仅30%,LV组仅40%存活,LA组动物生存时间明显延长(P〈0.01)。结论:AS—CLB1可以明显增强抗LL/2细胞在体内外的增殖作用,此增强效应可能与AS—CLB1诱导细胞发生C1期阻滞厦凋亡,增强了抗肿瘤作用有关。

英文摘要:

Objective: To study the effect of full-length cyclin B1 antisense cDNA(AS-CLB1) on Taxotere in inhibiting proliferation of Lewis lung carcinoma cells (LL/2) in vitro and in vivo and to provide the foundation for the feasibility of treating human hmg cancer and other malignancies with AS-CLB1 combined with Taxotere. Methods: LL/2 parent cells, LL/2/ vector and LL/2/AS-CLB1 transfectants(LP, LV and LA cells) were treated with Taxotere(0.01 nmol/L-0.1 μmol/L) in vit- ro. The cytotoxicity of Taxotere was evaluated by MTT assay types of cells, C57BL/6 mice were treated with Taxotere (15 mg/kg/day) once every three days for four eycles. Cell cycle anti apoptosis in the tumor tissues were determined by flow eytometry. Results: The survival rate of LA cells treated with taxotere was lower than that of the controls (LP and LV cells; P〈0.05). At Ih after treatment with taxotere (80nmol/L), the survival rate was (4.56±1.21)% in LA cells, (46.26±3.53)% in LP cells and (44.25±2.21)% in LV cells. At 24h after treatment with 20nmol/L Taxotere, the survival rate was (5.21±1.39)% in LA cells, whereas it was (36.17±3.63)% in LP and (35.15±3.63)% in LV cells. The tumor volume in the LA group was also lower than that of the controls(LP and LV group; P〈0.05). At 30 days after the inoculation of tumor cells. the tumor vohune was 421.68±30.16mm^3 in the LA group, 1981.29±318.56mm^3 in the LP group and 1673.36±297.96mm^3 in the LV group. Compared with the control groups, the cells in tumor tissues of the LA group showed G1 arrest and increased apoptosis(p〈0.05). There were (89.7±0.5)% cells in G1 phase and the apoptotic ratio was (79.5±1.2)% in the LA group. Moreover, 70% of the mice in the LA group were still alive at the end of the observation period for the survival studies. In contrast, only 30% of the mice in the LP group and 40% of the mice in the LV group were still alive. The survival rate in the LA group was significantly higher than in

同期刊论文项目
同项目期刊论文
期刊信息
  • 《中国肿瘤临床》
  • 中国科技核心期刊
  • 主管单位:中国科学技术协会
  • 主办单位:中国抗癌协会
  • 主编:郝希山
  • 地址:天津市河西区体院北环湖西路天津肿瘤医院C楼3层
  • 邮编:300060
  • 邮箱:cjco@cjco.cn
  • 电话:022-23527053
  • 国际标准刊号:ISSN:1000-8179
  • 国内统一刊号:ISSN:12-1099/R
  • 邮发代号:6-18
  • 获奖情况:
  • 1997、1999、2001三次获中国科协优秀期刊奖励基金,2001年获天津市科技期刊一等奖,1996年获中国科协优秀期刊三等奖,2011年天津市优秀期刊提名奖,2011年中国精品科技期刊
  • 国内外数据库收录:
  • 美国化学文摘(网络版),波兰哥白尼索引,荷兰文摘与引文数据库,荷兰医学文摘,日本日本科学技术振兴机构数据库,中国中国科技核心期刊,中国北大核心期刊(2004版),中国北大核心期刊(2008版),中国北大核心期刊(2011版),中国北大核心期刊(2014版),中国北大核心期刊(2000版)
  • 被引量:37940